Article
Author(s):
The FDA has approved GlaxoSmithKline's pazopanib (Votrient) to treat patients with advanced renal cell carcinoma.
Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment
Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
Darolutamide plus ADT shows mHSPC benefit regardless of disease volume
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
Darolutamide is safe, efficacious in mHSPC regardless of patient age
Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC